IGF2BP2 remodels the lung metastatic immune microenvironment to promote bladder cancer metastasis.

IGF2BP2 promotes bladder cancer lung metastasis by enhancing complement C3 translation and remodeling the immune microenvironment.

• Why it matters: Understanding the mechanisms behind bladder cancer metastasis is crucial due to its heterogeneity and therapeutic challenges, especially in the lung.
• What they did: Researchers established a lung-tropic bladder cancer subline and used multiomics analyses, showing IGF2BP2 expression increases during metastasis and binds to m6A-modified C3 mRNA to promote its translation.
• The result: Inhibiting IGF2BP2 reduced neutrophil recruitment and metastasis in vivo, and high IGF2BP2 levels in patients correlated with advanced disease and poor survival, suggesting it as a therapeutic target.